Holen Sie sich die Stockscreener-App
4.41
2.65%
-0.12
Handel nachbörslich:
4.51
0.10
+2.27%
Schlusskurs vom Vortag:
$4.53
Offen:
$4.68
24-Stunden-Volumen:
93,641
Relative Volume:
0.31
Marktkapitalisierung:
$2.21M
Einnahmen:
$12.99M
Nettoeinkommen (Verlust:
$-23.72M
KGV:
-1.3404
EPS:
-3.29
Netto-Cashflow:
$-23.28M
1W Leistung:
+7.82%
1M Leistung:
-58.90%
6M Leistung:
-77.93%
1J Leistung:
-98.54%
1-Tages-Spanne:
$4.2259
$4.73
1-Wochen-Bereich:
$3.65
$4.90
52-Wochen-Spanne:
$3.65
$399.60
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Firmenname
Aptevo Therapeutics Inc
Sektor
Branche
Telefon
206-838-0500
Adresse
2401 4TH AVE., SEATTLE, WA
Vergleichen Sie APVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
4.41 | 2.21M | 12.99M | -23.72M | -23.28M | -97.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-11-05 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-10-05 | Fortgesetzt | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Aktie (APVO) Neueste Nachrichten
Aptevo Therapeutics Stock Draws Retail Attention After Leukemia Trial Data: Retail Extremely Bullish - MSN
APVO stock touches 52-week low at $5.1 amid sharp annual decline - Investing.com Australia
Aptevo Therapeutics Inc. Announces 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline Aml Trial - Marketscreener.com
Aptevo reports full remission in AML trial - Investing.com India
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds - AccessWire
Aptevo reports full remission in AML trial By Investing.com - Investing.com UK
100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial - AccessWire
Aptevo's AML Drug Trial Hits 100% Remission Rate, Complete Cancer Cell Elimination in Phase 1b Study - StockTitan
(APVO) On The My Stocks Page - Stock Traders Daily
Aptevo Therapeutics executes reverse stock split - Investing.com India
Aptevo Therapeutics executes reverse stock split By Investing.com - Investing.com Australia
Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects - AccessWire
Aptevo's Novel Prostate Cancer Therapy Shows Promise in Preclinical Studies, Targets $24B Market - StockTitan
Sweden’s Alligator Makes Cuts To Avoid Extinction - Citeline News & Insights
Alligator Bioscience completes a rights issue of SEK 280 million - Marketscreener.com
Alligator Bioscience to make a rights issue of units of SEK 199 million - Marketscreener.com
Aptevo Therapeutics announces 1-for-37 reverse stock split By Investing.com - Investing.com Nigeria
Stock Market Movers Today • Top Gainers & Losers - Benzinga
What's Going On With Aptevo Therapeutics Shares Friday? - Benzinga
Aptevo Therapeutics Announces 1-for-37 Reverse Stock Split - Marketscreener.com
Aptevo Therapeutics announces 1-for-37 reverse stock split - Investing.com
Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan - AccessWire
Aptevo Therapeutics Announces 37-to-1 Reverse Split to Meet Nasdaq Requirements | APVO Stock News - StockTitan
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation - AccessWire
Aptevo to Showcase Cancer Therapy Platform at Major Healthcare Conference | APVO Stock News - StockTitan
Does Aptevo Therapeutics Inc (NASDAQ: APVO) Still Look Hot This Week? - Stocks Register
Aptevo reports progress in cancer antibody trials By Investing.com - Investing.com Australia
Aptevo reports progress in cancer antibody trials - Investing.com India
Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm - AccessWire
Aptevo's Cancer Drug Shows 90% Blast Reduction in AML Trial, Pipeline Advances | APVO Stock News - StockTitan
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies - AccessWire
Aptevo's AML Drug Shows 90% Cancer Reduction in Early Trial Results | APVO Stock News - StockTitan
Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated at StockNews.com - Defense World
Armistice Capital, LLC's Strategic Acquisition of Aptevo Therape - GuruFocus.com
Alligator Bioscience reports positive results for APV-527 in Phase 1 study - Marketscreener.com
Alligator Bioscience announces positive results for APV-527 - Marketscreener.com
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial - AccessWire
Aptevo's Cancer Drug Shows Promise: 56% of Patients Achieve Disease Stability in Phase 1 | APVO Stock News - StockTitan
Hudson Bay Capital Management LP's Strategic Acquisition in Aptevo Therapeutics Inc - GuruFocus.com
Aptevo Therapeutics Inc (APVO) Quarterly 10-Q Report - Quartz
Aptevo Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update - AccessWire
Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated by Analysts at StockNews.com - Defense World
Alligator Bioscience to present positive data for mitazalimab at SITC - Marketscreener.com
Aptevo Therapeutics Inc (NASDAQ: APVO) Has Great Upside Potential - Stocks Register
Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com - Defense World
Alligator Bioscience presents positive interim data from Phase 1 study - Marketscreener.com
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024 - AccessWire
Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update - Defense World
Aptevo Therapeutics secures shareholder nod for key proposals By Investing.com - Investing.com South Africa
Finanzdaten der Aptevo Therapeutics Inc-Aktie (APVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):